论文部分内容阅读
目的 探讨异基因造血干细胞移植 (Allo HSCT)治疗白血病的疗效、造血重建及生存情况。方法 白血病患者 10例 ,其中同胞间HLA相合的异基因外周血干细胞移植 (Allo PBSCT)7例 ,无亲缘关系HLA不全相合脐血移植 (UCBT) 3例。结果 9/10例受者获造血重建 ,UCBT患者造血重建速度较HLA相合的同胞PBSCT慢 ,1例UCBT移植后 35天造血未重建 ,回输自体外周血干细胞后 ,仍未能重建造血 ,于 72天死亡。其余至今均无病生存。结论 Allo HSCT是目前治愈白血病的有效方法 ,对于无同胞HLA相合的供者 ,选择细胞数量较高、HLA 1～ 2个位点不合的UCBT仍然有效可行。
Objective To investigate the efficacy, hematopoietic reconstitution and survival of allogeneic hematopoietic stem cell transplantation (Allo HSCT) in the treatment of leukemia. Methods Totally 10 leukemia patients, including 7 allogeneic peripheral blood stem cell transplantation (HLA-matched allogeneic peripheral blood stem cell transplantation) and 3 unrelated unrelated HLA-matched umbilical cord blood transplantation (UCBT). Results 9/10 recipients received hematopoietic reconstitution. UCBT patients had a slower rate of hematopoietic reconstitution than PBS-matched siblings. One case of UCBT did not reconstruct on the 35th day after autologous peripheral blood stem cells transplantation. 72 days dead. The rest have so far been disease-free. Conclusions Allo HSCT is an effective method for the treatment of leukemia. For those donors with no sibling HLA matching, UCBT with high number of cells and 1 to 2 HLA mismatches is still valid and feasible.